Catalog No.
Product Name
Application
Product Information
Citations
-
HSV-1 Inhibitor
Soyasapogenol C is an oleanane-type triterpenoid that demonstrates significant antiviral activity against herpes simplex virus type 1 (HSV-1). With an IC50 value of 18.9 μM, it effectively inhibits viral replication, making it a valuable compound for research in virology and therapeutic development against HSV-1 infections. Its unique mechanism of action and biological potency position Soyasapogenol C as a candidate for further exploration in antiviral studies. -
HSV-1 Inhibitor
5-Nitrobarbituric acid functions as an inhibitor of herpes simplex virus type-1 (HSV-1), exhibiting an IC50 of 1.7 μM. This compound has demonstrated potential in virology research, particularly in studies aiming to understand and combat HSV-1 infections. Its utility in antiviral drug development positions it as a valuable tool for researchers exploring therapeutic strategies against herpes simplex viruses. -
HSV Inhibitor
1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil is a nucleoside analogue that specifically targets herpes simplex virus (HSV). This compound exhibits potent antiviral activity by inhibiting viral replication. It is utilized in research focused on developing therapeutic strategies for HSV infections and studying viral pathogenesis. -
HSV Polymerases Inhibitor
PNU-183792 is a potent inhibitor of herpes simplex virus (HSV) polymerases, classified as a 4-oxo-dihydroquinoline. It demonstrates broad-spectrum antiviral activity, exhibiting IC50 values of 0.69 μM for human cytomegalovirus (HCM), 0.37 μM for varicella zoster virus, and 0.58 μM for HSV polymerases. Importantly, PNU-183792 operates selectively, showing no activity against human α, γ, or δ polymerases. Additionally, it exhibits inhibitory effects on simian varicella virus (SVV), murine cytomegalovirus (MCMV), and rat cytomegalovirus (RCMV), making it a valuable tool for antiviral research. -
HSV-1 Inhibitor
Leachianone G is an antiviral flavonoid derived from the root bark of Morus alba L., targeting herpes simplex virus type 1 (HSV-1). It exhibits significant antiviral activity, demonstrating an IC50 value of 1.6 μg/mL. This compound may be utilized in research focused on antiviral therapeutics and the mechanisms of HSV-1 infection. -
HSV Inhibitor
HN0037 is a selective helicase-primase inhibitor targeting the herpes simplex virus (HSV). By interfering with the viral helicase-primase complex composed of UL5, UL52, and UL8 proteins, HN0037 effectively inhibits HSV replication. Its mechanism of action makes it a valuable research tool for studying antiviral therapies and HSV pathogenesis. -
HSV Inhibitor
5'-Ethynyl-2'-deoxycytidine is a potent inhibitor of herpes simplex virus (HSV), effectively reducing the cytopathic effects of HSV-1 in primary rabbit kidney cells with a minimum inhibitory concentration (MIC) of 0.2 μg/mL. Additionally, this compound demonstrates anti-proliferative activity against leukemia L1210 cells, exhibiting an IC50 value of 64.5 μg/mL. It serves as a valuable tool for researchers investigating viral infections and cancer biology. -
HSV Inhibitor
Stearyl gallate, an alkyl gallate with an 18-carbon long alkyl chain, primarily functions as an antiviral agent against herpes simplex virus type 1 (HSV-1). This compound exhibits notable antioxidant properties, making it a useful tool in research focused on viral inhibition and oxidative stress. Its multifaceted biological activity positions stearyl gallate as a candidate for further investigation in the development of therapeutic agents targeting viral infections. -
HSV Inhibitor
Tromantadine is an effective inhibitor of herpes simplex virus (HSV) replication, specifically targeting HSV-1 and HSV-2. As a derivative of Amantadine, it demonstrates significant antiherpetic activity, making it suitable for research applications focused on viral infection mechanisms and potential therapeutic interventions. -
HSV-1 Protease Substrate
HSV-1 Protease Substrate is a peptide substrate specifically designed for the HSV-1 protease. It exhibits a specificity constant (kcat/Km) for cleavage of 5.2 M-1 s-1 at pH 7.5, making it an essential tool for studying HSV-1 protease activity. This substrate is valuable in research applications focused on herpesvirus biology, proteolytic processing, and the development of antiviral strategies. -
HSV
ISIS 1082 is an antisense oligonucleotide designed to target the translation initiation codon of herpes simplex virus (HSV) type 1 and 2 virion capsid protein. This compound effectively inhibits HSV-1 replication in vitro, demonstrating its potential as a research tool in elucidating the mechanisms of HSV pathogenesis and developing therapeutic strategies against HSV infections. Its specificity to viral targets makes it invaluable for studies in virology and molecular biology. -
HSV Inhibitor
Ganoderone A is a triterpene compound known for its inhibitory activity against herpes simplex virus (HSV). With an IC50 value of 0.3 µg/mL, it demonstrates significant antiviral properties. Ganoderone A shows promise for applications in the treatment of viral infections and may also have relevance in cancer research. -
HSV Inhibitor
11-Deoxymogroside IIE is a cucurbitane glycoside derived from the fruits of Siraitia grosvenorii, primarily targeting viral inhibition. It exhibits notable inhibitory effects against the activation of the Epstein-Barr virus (EBV-EA) when induced by TPA. Additionally, it demonstrates a weak inhibitory effect on the nitric oxide donor, NOR1. This compound serves as a valuable tool for research focused on viral infections and their mechanisms. -
HSV-1/2 Inhibitor
Peniterphenyl A is a potent inhibitor of herpes simplex virus types 1 and 2 (HSV-1/2) through direct interaction with the viral envelope glycoprotein D. It effectively blocks the entry of the virus into host cells, thereby preventing infection by disrupting virus adsorption and membrane fusion processes. This natural product, derived from a deep-sea Penicillium species, represents a promising lead compound for further research and development in the field of antiviral therapeutics against HSV-1 and HSV-2. -
Anti-HSV-1 Control
Makisterone A 2-acetate is a steroid compound isolated from the 75% ethanol extract of Cyanotis arachnoidea. Despite its structural potential, experimental findings indicate that it exhibits no anti-HSV-1 activity. This compound may serve as a reference or control in research focused on herpes simplex virus type 1 and other related investigations in virology and pharmacology. -
HSV-1 Inhibitor
WAY-150138 is a selective inhibitor of herpes simplex virus type 1 (HSV-1), functioning by obstructing the incorporation of DNA-packaging proteins into viral capsids during assembly. This compound demonstrates potent antiviral activity against HSV-1 and may serve as a valuable tool for studying the mechanisms of viral replication and the development of antiviral therapies. Its application in research on HSV-1 will aid in understanding the virus's life cycle and identifying potential therapeutic interventions. -
HSV-1/2 Inhibitor
HSV-1/HSV-2-IN-2 is an inhibitor of both HSV-1 and HSV-2, displaying effective antiviral activity with EC50 values of 6.8 µM and 8.9 µM, respectively. This compound is also active against Varicella Zoster Virus (VV), with an EC50 value of 8.9 µM. HSV-1/HSV-2-IN-2 is suitable for research applications focused on understanding herpesvirus biology and potential therapeutic strategies. -
HSV-1/HSV-2 Inhibitor
HSV-1/HSV-2-IN-1 is a potent inhibitor targeting both HSV-1 and HSV-2 with EC50 values of 7.6 µM for HSV-1 (KOS) and 7.6 µM for HSV-2 (G). It also demonstrates activity against HSV-1 TK- KOS ACVr and vaccinia virus, showing EC50 values of 4 µM and 12 µM, respectively, in human embryonic lung fibroblast cell cultures. This compound is suitable for research focused on antiviral therapies and the mechanisms of herpesvirus infection. -
Antiviral Agent
Antiviral Agent 58 (Compound J1) is an orally active compound that exhibits broad-spectrum antiviral activity against enveloped viruses. It targets a variety of viral pathogens, including influenza A virus (IAV), respiratory syncytial virus (RSV), SARS-CoV-2, human coronavirus OC43 (HCoV-OC43), and both herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). This agent is of significant interest for research applications focusing on the treatment of viral infections. -
Anti-HSV Compound
Acyclovir elaidate is an orally active anti-HSV compound and a derivative of Acyclovir. This reagent effectively alleviates clinical symptoms of genital herpes in experimental female guinea pig models. Its potential utility in studying herpes simplex virus infections makes it a valuable tool for researchers in virology and infectious disease. -
HSV Inhibitor
Karalicin is an antiviral agent that functions as an inhibitor of herpes simplex virus (HSV-1 and HSV-2), vaccinia virus, and poliovirus type I. It exhibits potent inhibitory activity, with IC50 values of 0.004 μg/mL for HSV-1, 0.008 μg/mL for HSV-2, and 0.016 μg/mL for both vaccinia virus and poliovirus type I. This compound is valuable for research into antiviral therapies and the mechanistic study of viral infections. -
HSV-1/2 Inhibitor
5-(4-Carboxyphenyl)-10,15,20-triphenylporphyrin is a porphyrin compound that targets herpes simplex viruses 1 and 2 (HSV-1/2). It demonstrates potent virucidal activity, achieving inhibition rates of 85% against HSV-1 and 60% against HSV-2, with a maximum noncytotoxic concentration of 5 μg/mL on Vero cells. This compound serves as a valuable tool for studying antiviral mechanisms and can facilitate the synthesis of derivatives with enhanced antiviral efficacy. -
HSV-1 Inhibitor
17,17-Ethylendioxyandrost-5-en-3β-ol acts as an inhibitor of herpes simplex virus type 1 (HSV-1), displaying an EC50 value of 629 μM. This compound is relevant for research focused on viral infections and can be utilized to explore mechanisms of viral replication and potential therapeutic strategies against HSV-1. -
HSV-2 Inhibitor
SCH-43478 is a non-nucleoside antiviral agent that targets herpes simplex virus type 2 (HSV-2). It exhibits potent and selective activity with an IC50 of 1.8 μg/mL in Vero cells. Additionally, SCH-43478 shows significant efficacy in preclinical models of HSV infection, specifically in the guinea pig genital model, making it a valuable tool for research on antiviral therapies. -
HSV-1/HSV-2 Inhibitor
HSV-1/HSV-2-IN-3 is a potent inhibitor of the herpes simplex virus (HSV) helicase-primase complex, effectively disrupting the DNA unwinding and primer synthesis necessary for viral genome replication. It demonstrates an EC50 of 7.0 nM against HSV-2 in gD-immunofluorescence assays, and 1.1 nM in qPCR replication assays, highlighting its potent antiviral activity. Additionally, HSV-1/HSV-2-IN-3 exhibits high selectivity for viral targets, with an IC50 of approximately 2.9 µM for human carbonic anhydrase II, making it a valuable tool for anti-HSV research applications. -
HSV Inhibitor
(S)-HN0037 is a selective helicase-primase inhibitor that effectively targets the viral helicase-primase complex, thereby inhibiting herpes simplex virus (HSV) replication. Its oral bioactivity makes it a valuable tool for studying HSV pathology and developing antiviral therapies. Researchers can utilize (S)-HN0037 in various experimental models to investigate mechanisms of viral replication and explore potential therapeutic interventions against HSV infections. -
HSV Inhibitor
C-AFG is a novel herpes simplex virus (HSV) inhibitor that demonstrates potent activity against both HSV-1 and HSV-2. This compound exhibits high selectivity, making it a valuable tool for research on viral infections and the mechanisms of antiviral action. C-AFG is suitable for studies focusing on therapeutic strategies against herpesvirus-related diseases. -
HSV Inhibitor
HSV-1-IN-3 is a potent inhibitor of herpes simplex virus (HSV) with demonstrated antiviral activity against both Acyclovir-sensitive and -resistant HSV strains. This compound has potential applications in virology research, particularly in studies focused on understanding and developing treatments for HSV infections. Its effectiveness against resistant strains makes it a valuable tool in the search for new antiviral therapies. -
HSV-1 Inhibitor
Woodorien is a potent inhibitor of herpes simplex virus type 1 (HSV-1), demonstrating strong antiviral activity. Isolated from the plant Woodwardia orientalis, Woodorien functions as a glucoside that impacts viral replication. This compound serves as a valuable tool for studying HSV-1 infection mechanisms and the development of antiviral therapies. -
Endonuclease Inhibitor
AV5116 is a cap-dependent endonuclease inhibitor that specifically targets the active site of the cap-dependent endonuclease (CEN) within the N-terminal domain of polymerase acidic. This compound demonstrates potent inhibitory activity against various influenza viruses, including types A, B, and C. AV5116 is valuable for research investigating influenza virus infections and the mechanisms of antiviral action. -
Influenza Virus Inhibitor
β-Cyclodextrin is a cyclic polysaccharide that targets influenza virus inhibition, specifically effective against the H1N1 strain. Its primary mechanism involves enhancing the solubility of various compounds, making it a valuable tool in virology research. Additionally, β-Cyclodextrin demonstrates significant antiviral activity, providing potential therapeutic applications in the treatment of influenza. -
Neuraminidase Inhibitor
2,3-Dehydro-2-deoxy-N-acetylneuraminic acid is a potent inhibitor of neuraminidase enzymes, functioning primarily through competitive inhibition. This compound demonstrates significant inhibitory effects on human neuraminidase isoforms NEU1, NEU2, NEU3, and NEU4, with IC50 values of 143, 43, 61, and 74 μM, respectively. Its inhibitory activity positions it as a valuable tool for researching anti-influenza virus mechanisms and for studying sialidase-related biological processes. -
Influenza Viru Inhibitor
Desaminotyrosine is an influenza virus inhibitor that enhances type I interferon signaling. This microbial metabolite plays a crucial role in the immune response against influenza, offering protective effects by promoting antiviral activity. Its mechanism of action makes it valuable for research into antiviral therapies and immune modulation strategies. -
Influenza Viru Inhibitor
L-Norleucine, a derivative of leucine, primarily functions as an antiviral agent by inhibiting protein synthesis, particularly in the context of influenza virus infections. Its activity interferes with viral replication, making it a valuable reagent for research applications focused on viral biology and therapeutic interventions against influenza. L-Norleucine can be utilized in studies exploring mechanisms of protein synthesis modulation and the development of antiviral strategies. -
Non-ionic Detergent
Octaethylene glycol monododecyl ether (C12E8) functions as a non-ionic detergent, primarily utilized for solubilizing membrane proteins. This compound effectively disrupts lipid bilayers, making it a valuable tool for extracting membrane proteins and studying their structure and function. Additionally, C12E8 demonstrates the ability to solubilize the viral membrane of intact influenza virus, facilitating research in virology and membrane biochemistry. -
MTr1 Inhibitor
Trifluoromethyl-tubercidin (TFMT) is an inhibitor of the enzyme 2'-O-ribose methyltransferase 1 (MTr1). This compound effectively disrupts the cap-snatching mechanism utilized by influenza A and B viruses, thereby inhibiting viral replication. TFMT demonstrates notable antiviral activity with minimal toxicity, making it a valuable reagent for studies in virology and antiviral research. -
Influenza Virus Inhibitor
Epigoitrin is a natural alkaloid that exhibits antiviral activity against influenza viruses by inhibiting attachment and replication of the influenza A1 virus FM1 in vitro. This compound enhances the host's resistance to influenza infection, particularly under stress conditions. Additionally, Epigoitrin demonstrates lipid-lowering effects, making it a potential candidate for research in infectious diseases and metabolic health. -
Influenza Viru
Influenza A NP(366-374) Strain A/PR/8/35 is a peptide derived from the nucleoprotein of Influenza A virus, specifically restricted by the H2-Db major histocompatibility complex. This epitope plays a crucial role in immune response studies and can be utilized in vaccine development and T cell activity assays. It aids in understanding the immune recognition of influenza virus and contributes to research focused on viral pathogenesis and host immunity. -
Influenza Virus Inhibitor
2′-Deoxy-2′-fluoroguanosine is a nucleoside analog that serves as a potent inhibitor of influenza viruses, exhibiting an effective concentration (EC90) of less than 0.35 μM against both influenza A and B strains. This compound disrupts the replication process of the influenza virus in the upper respiratory tract, resulting in reduced fever and alleviated nasal inflammation. Its antiviral properties make it a valuable tool for research on influenza virus pathogenesis and therapeutic intervention strategies. -
Influenza Virus Inhibitor
Rupestonic acid is a sesquiterpene that acts as an inhibitor of the influenza virus. This compound demonstrates significant antiviral activity, making it a valuable tool for research focused on influenza virus pathogenesis and therapeutic interventions. Its ability to disrupt viral replication holds potential for the development of novel antiviral strategies. -
Kinase Inhibitor
3-Deoxysappanchalcone is a potent kinase inhibitor that selectively targets MET, EGFR, AKT, mTOR, p38 MAPK, JNK, thrombin, FXa, and influenza virus neuraminidase, modulating key signaling pathways. This compound is known to induce cell cycle arrest, reactive oxygen species (ROS) production, and apoptosis, demonstrating significant biological activities. Its anti-inflammatory, anti-allergic, anticoagulant, and antithrombotic properties make it valuable for research in gefitinib-resistant lung cancer, esophageal squamous cell carcinoma, thrombosis, and influenza virus infections. -
Anti-influenza Drug
Clemastanin B is a lignan with potent anti-influenza activity, primarily through inhibition of viral multiplication, prophylaxis, and blockade of virus attachment. It targets key processes in the viral lifecycle, including endocytosis, uncoating, and the export of ribonucleoprotein (RNP) from the nucleus. Additionally, Clemastanin B exhibits antioxidant and anti-inflammatory properties, making it a valuable compound for research into viral infections and inflammatory responses. -
Antiviral Drug
Azaribine, a potent inhibitor of orotidine monophosphate decarboxylase (OMPD), serves as an effective antiviral agent against several RNA viruses. It disrupts viral genome replication and gene transcription, demonstrating broad-spectrum antiviral activity with EC50 values ranging from 3.80 nM to 1.73 μM against influenza A and B viruses, and an EC50 of 1.62 μM against Zika virus (ZIKV Paraiba). Additionally, Azaribine holds potential for research applications related to psoriasis. -
Specialized Proresolving Mediator
17-HDHA is a specialized proresolving mediator derived from docosahexaenoic acid (DHA). It plays a critical role in enhancing the antibody-mediated immune response against influenza virus by promoting the differentiation of B cells into CD27+ CD38+ antibody-secreting cells. This action significantly increases the production of immunoglobulin M (IgM) and immunoglobulin G (IgG) by activated B cells, making it a valuable tool for research into immune response and resolution of inflammation. -
Antiviral Agent
Salcomine is an N,N’-Bis(salicylidene)ethylenediaminocobalt(II) complex that acts as a potent antiviral agent, specifically targeting influenza viruses. This compound demonstrates significant biological activity by inhibiting viral replication. Salcomine is valuable in research applications aimed at understanding virus-host interactions and developing antiviral therapies. -
Influenza Virus Inhibitor
Oseltamivir-d3 is a deuterium-labeled derivative of Oseltamivir, which functions as a neuraminidase inhibitor targeting the influenza virus. This compound demonstrates potent antiviral activity against various influenza strains, including A/H3N2, A/H1N2, A/H1N1, and B, with mean IC50 values of 0.67, 0.9, 1.34, and 13 nM, respectively. Oseltamivir-d3 is valuable for research applications focused on influenza virus studies, antiviral drug development, and mechanistic investigations of neuraminidase inhibition. -
Hepatitis B Inactivator
DL-Pyroglutamic acid functions as an inactivator of the hepatitis B virus by targeting its surface proteins. In addition to its antiviral activity against vaccinia virus, herpes simplex virus, and influenza virus, DL-Pyroglutamic acid may also inhibit GABA transaminase, leading to increased levels of GABA. This mechanism suggests potential antiepileptic effects, making it valuable for research in virology and neurology. -
CEN Inhibitor
AV5124 is an orally active cap-dependent endonuclease (CEN) inhibitor, functioning as a prodrug of AV5116. It exhibits potent antiviral activity by inhibiting the endonuclease function essential for influenza virus replication. This compound is primarily utilized in research focused on developing antiviral strategies against influenza and understanding viral RNA synthesis mechanisms. -
IAV Inhibitor
VNT-101 is an orally active inhibitor of influenza A virus (IAV) that targets the nucleoprotein (NP) and disrupts NP-NP protein-protein interactions, leading to the destabilization of the viral ribonucleoprotein complex. This compound demonstrates potent antiviral activity across various IAV subtypes, with EC50 values ranging from 4-5 nM in cellular cytopathic effect assays, 4-8 nM in neuraminidase assays, and 21-45 nM in ribonucleoprotein assays. Additionally, VNT-101 shows significant in vivo antiviral efficacy in mice infected with lethal H1N1 virus, making it a valuable tool for studying influenza A infection and potential therapeutic interventions. -
Adjuvant
Polygalasaponin XXXI, also known as Onjisaponin F, functions as an effective adjuvant, enhancing the immune response when administered intranasally alongside influenza hemagglutinin (HA) vaccines. This compound supports the development of protective immunity against influenza virus infection, making it valuable in vaccine formulation research and development. Its adjuvant properties are crucial for optimizing vaccine efficacy and improving overall immune defense strategies.
